Biotech startup aims to tackle chronic back pain [Video]

Petah Tikva-based Discure Technologies has raised $16 million in funding to advance its novel treatment for degenerative disc disease (DDD), a common cause of chronic back pain.

The medical device startup, founded by Rainbow Medical Innovations in Herzliya, recently secured $11 million in an oversubscribed Series A financing round. This follows a previous $5 million raised through a SAFE (Simple Agreement for Future Equity) round, bringing the total equity financing to $16 million.

Unlike current treatments that only manage symptoms, Discure’s technology targets the cause of DDD. 

“Rather than starting opioid treatment and getting into the vicious cycle of opioid use, the alternative is treating with the Discure system to stop and reverse degeneration,” says CEO Yuval Mandelbaum.

The system under development by the company is a minimally invasive, implantable bioelectronic device. 

“We inject a minuscule electrode under local anesthesia into the center of the [affected] disc. This electrode allows us to actively control the negative charge inside the disc, …